Mr. Andrew Lin’s appointment as Chairman of TaiRx, Inc. is effective as of December 9, 2020.
2020/12/9 Andrew Lin received his master’s degree of Business Administration (MBA) from the University of Chicago. He is one of the very few [...]
About Chang Lisa
This author has not yet filled in any details.So far Chang Lisa has created 44 blog entries.
TaiRx’s anti-cancer drug CVM-1118 won the renewal of Excelsior Award in 2020.
2020/12/1 Having been awarded the 12th National Innovation Award in 2015 and the Excelsior Award in 2019, TaiRx’s anti-cancer drug CVM-1118 won the [...]
TaiRx successfully raised 504 million NTD in capital.
2020/11/27 To enrich working capital, TaiRx has successfully raised 504 million NTD on October 28, 2020, and issued common shares on November 27, [...]
TaiRx ranked first in Taiwan for the most innovative pharmaceutical companies in the APAC region
2019/8/30 World-renowned professional information services company, Clarivate Analytics, released a special report, “Pharmaceutical Innovation in the APAC Region – A Quantitative Company Ranking [...]
TaiRx receives “Technology and Product or Technology Development is Successful and Marketable” recommendation from Industrial Development Bureau and starts CVM-1118 (Foslinanib) Phase II clinical trial in Taiwan and US.
2019/1/2 TaiRx, Inc. (6580) announces good news at the start of 2019 that it receives “Technology and Product or Technology Development is Successful [...]
TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics- Joint venture to focus on the Nodal protein, a previously untargeted and critical mediator of aggressive cancer progression and treatment resistance
2018/10/23 TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the [...]
A major milestone for cancer drug development in Taiwan! CVM-1118 approved by the US FDA to start Phase II clinical study in the US.
2018/4/15 TaiRx’s CVM-1118 small molecule cancer drug received US FDA approval on April 15th to conduct multi-nation, multi-center Phase II clinical trial in [...]
A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.
2018/3/8 TaiRx, Inc. (6580) announces today that its new injection product, Zelnite®, received NDA approval from the Taiwan FDA on January 22nd, 2018. [...]
TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.
2017/10/31 Lee WJ, Chen YL, Chu YW, Chien DS. Comparison of glutathione peroxidase-3 protein expression and enzyme bioactivity in normal subjects and patients with sepsis. Clin Chim Acta. [...]
TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.
2017/8/22 TaiRx Announces License Agreement with Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago, for Nodal Patents to Develop [...]